Novelty:
A cell line comprising the TC-1 P3 subclone to serve as an immune resistant tumor model for cancer immunotherapy research.
Value Proposition:
Many human tumors demonstrate downregulation of MHC class I molecule expression as a means of immune evasion. Thus, the development of a suitable tumor model with downregulated MHC class I expression is critical for designing vaccines and immunotherapeutic strategies to control such tumors. This invention is a cell line containing the TC-1 P3 (A15) subclone that has downregulated MHC class I expression for testing immunotherapeutic strategies. Other advantages include:
• Subclone exhibits downregulation of MHC class I compared to original TC-1 cells
• Effective murine tumor models can be generated using the cell line
• Suitable tool for cancer vaccine design and other immunotherapeutic strategies
• In vivo tumor model
Technical Details:
Johns Hopkins researchers have developed a cell line with downregulated MHC class I expression to serve as immune resistant tumor models. ThisTC-1 P3 (A15) subclone was derived from TC-1 P3 cells, an immune resistant cell line. The cells can be injected into mice intravenously to generate in vivo tumor models to serve as a platform for therapeutic interventions.
Looking for Partners:
To license the technology as a tumor model to develop cancer therapeutics.
Stage of Development:
Cell line established
Data Availability:
Animal data
Publications/Associated Cases:
Gene Ther. 2003 Aug;10(16):1311-20
